{"id":390501,"date":"2019-01-04T00:00:00","date_gmt":"2019-01-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2019-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-without-diarrhea\/"},"modified":"2026-05-01T11:39:40","modified_gmt":"2026-05-01T11:39:40","slug":"algoim0056-2019-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-without-diarrhea","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2019-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-without-diarrhea\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS Without Diarrhea (Including IBS-Constipation) | US | 2019"},"content":{"rendered":"<p>Irritable bowel syndrome (<abbr title=\"irritable bowel syndrome\">IBS<\/abbr>) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes, constipation predominant, diarrhea predominant, and mixed; however, prior to 2017, only two <abbr title=\"International Statistical Classification of Diseases and Related Health Problems, 10th revision\">ICD-10<\/abbr> codes existed: <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> with diarrhea and <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea. For the purposes of this analysis, we focus on the <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea population, which includes <abbr title=\"irritable bowel syndrome\">IBS<\/abbr>-constipation (<abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr>). Limited treatment options are available for <abbr title=\"irritable bowel syndrome\">IBS<\/abbr>, and only a few drugs have secured an <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval for <abbr title=\"constipation-predominant irritable bowel syndrome\">IBS-C<\/abbr>. Current treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan\u2019s Linzess and Synergy Pharmaceuticals\u2019 Trulance), and bicyclic fatty acids (Takeda\u2019s Amitiza), all of which are only moderately effective in treating the disease.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li><!--[endif]-->What patient share do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea (including <abbr title=\"irritable bowel syndrome\">IBS<\/abbr>-C)patients? What are the quarterly trends in prescribing among recently treated and new diagnosed <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea (including <abbr title=\"irritable bowel syndrome\">IBS<\/abbr>-C) patients?<\/li>\n<li><!--[endif]-->How have Linzess and Trulance been integrated into the treatment algorithm?<\/li>\n<li>What proportion of <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea (including IBS-C) patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea (including <abbr title=\"irritable bowel syndrome\">IBS<\/abbr>-C) patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"irritable bowel syndrome\">IBS<\/abbr> without diarrhea (including <abbr title=\"irritable bowel syndrome\">IBS<\/abbr>-C)?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis <\/em>provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390501","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390501\/revisions"}],"predecessor-version":[{"id":393625,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390501\/revisions\/393625"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}